Phase

PHASE1 clinical trials

Active studies categorized as PHASE1 in the public registry.

213active studies

125recruiting now

30countries represented

22largest site network

Current studies

Status and location data reflect the registry snapshot built 2026-09-08. Verify the original record before contacting a site.

Recruiting nowPhase 1

Graded Insulin Suppression Test P&F

Insulin Resistance, HyperinsulinemiaCondition

Insulin regular, 2.0-3.2 mU/m2/min (euinsulinemia), Insulin regular, 32 mU/m2/min (hyperinsulinemia)Treatment

United States1 locations

Columbia UniversitySponsor

Updated 2026-09-08 · NCT06592261See eligibility →

Recruiting nowPhase 1

Phase 1 Clinical Study of MWN105 Injection in Participants With Overweight or Obesity

Overweight , Obesity, Type 2 Diabetes Mellitus (T2DM)Condition

MWN105 1, MWN105 2Treatment

China1 locations

Shanghai Minwei Biotechnology Co., LtdSponsor

Updated 2026-09-08 · NCT07803809See eligibility →

Recruiting nowPhase 1

A First-in-human Research Study on How NNC0721-8060 Works in People Living With Overweight or Obesity

Overweight, ObesityCondition

NNC0721-8060, SemaglutideTreatment

United States2 locations

Novo Nordisk A/SSponsor

Updated 2026-09-04 · NCT07767175See eligibility →

Recruiting nowPhase 1

A Study Investigating the Safety of RO7795081 and the Effect of RO7795081 on How the Body Processes Pitavastatin and Rosuvastatin in Otherwise Healthy Overweight or Obese Adult Participants

Overweight, ObesityCondition

RO7795081, PlaceboTreatment

Netherlands1 locations

Hoffmann-La RocheSponsor

Updated 2026-09-03 · NCT06982131See eligibility →

Recruiting nowPhase 1

A Study to Evaluate ALN-6222 in Participants With Obesity

ObesityCondition

ALN-6222, PlaceboTreatment

Canada1 locations

Alnylam PharmaceuticalsSponsor

Updated 2026-09-03 · NCT07624071See eligibility →

Recruiting nowPhase 1

Alpelisib Challenge Test (ACT)

Insulin Resistance, Type 2 DiabetesCondition

Alpelisib 300 mg, Alpelisib Challenge Test (ACT): Mixed Meal Tolerance Test (MMTT) after taking alpelisibTreatment

United States1 locations

Columbia UniversitySponsor

Updated 2026-09-03 · NCT07778524See eligibility →

Recruiting nowPhase 1

A Research Study to See How NNC0487-0111 Affects the Body's Energy Use After a Weight Loss in Adults Living With Obesity, Compared to a Low-calorie Diet or Placebo

Overweight, ObesityCondition

NNC0487-0111, PlaceboTreatment

Denmark, Netherlands2 locations

Novo Nordisk A/SSponsor

Updated 2026-09-02 · NCT07757087See eligibility →

Recruiting nowPhase 1

A Study Investigating the Safety, Absorption, Elimination, and the Effect on the Immune System of ACI-19764 in Healthy Participants and in Participants With Cardiovascular Risk Factors

Healthy Participants, ObesityCondition

Placebo, ACI-19764 at dose A1Treatment

Netherlands1 locations

AC Immune SASponsor

Updated 2026-09-02 · NCT07463196See eligibility →

Recruiting nowPhase 1

A Study of LY4174794 in Participants With Obesity or Overweight Who Are Otherwise Healthy

Obesity, OverweightCondition

LY4174794, LY4174794Treatment

Singapore, United States3 locations

Eli Lilly and CompanySponsor

Updated 2026-09-01 · NCT07654972See eligibility →

Recruiting nowPhase 1, Phase 2

The Effect of SGLT2 Inhibition on Adipose Inflammation and Endothelial Function

Obesity, Metabolic SyndromeCondition

Empagliflozin 25 MG, PlaceboTreatment

United States1 locations

Vanderbilt University Medical CenterSponsor

Updated 2026-09-01 · NCT05972564See eligibility →

Recruiting nowPhase 1

A Study to See How Safe a New Medicine (NNC6022-0004) is in Healthy People and People Living With Obesity

Obesity, Elevated High-sensitivity C-reactive Protein (hsCRP)Condition

NNC6022-0004, PlaceboTreatment

Netherlands1 locations

Novo Nordisk A/SSponsor

Updated 2026-09-01 · NCT07693868See eligibility →

Recruiting nowPhase 1

A Clinical Trial Evaluating TQF3250 Capsules in Patients With Type 2 Diabetes Mellitus and Overweight/Obesity

Type 2 Diabetes Mellitus Combined With Overweight or ObesityCondition

TQF3250 capsules, TQF3250 placeboTreatment

China12 locations

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Sponsor

Updated 2026-08-28 · NCT07747857See eligibility →

Recruiting nowPhase 1, Phase 2

A Phase Ib/IIa Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Oral Ecnoglutide Tablets in Chinese Participants With Overweight or Obesity

Overweight and/or Obesity, Weight ManagementCondition

ecnoglutide tablets, placebo with matching dosageTreatment

China1 locations

Hangzhou Sciwind Biosciences Co., Ltd.Sponsor

Updated 2026-08-28 · NCT07243171See eligibility →

Recruiting nowPhase 1

A Research Study Looking Into How UBT251 Works With Birth Control Tablets and Emptying of the Stomach in Women With Excess Body Weight Not Able to Become Pregnant

Overweight, ObesityCondition

UBT251, Oral contraceptiveTreatment

Canada1 locations

Novo Nordisk A/SSponsor

Updated 2026-08-25 · NCT07710729See eligibility →

Recruiting nowPhase 1

Phase I Drug-Drug Interaction Study of UBT251 Injection in Participants With Overweight or Obesity

Drug Drug Interaction (DDI), Pharmacokinetics and PharmacodynamicsCondition

UBT251, Metformin hydrochlorideTreatment

China1 locations

The United Bio-Technology (Hengqin) Co., Ltd.Sponsor

Updated 2026-08-25 · NCT07785934See eligibility →

Recruiting nowPhase 1

Human Models of Selective Insulin Resistance: Alpelisib, Part I

Insulin Resistance, Prediabetic StateCondition

Alpelisib 300 mg, PlaceboTreatment

United States1 locations

Columbia UniversitySponsor

Updated 2026-08-24 · NCT06354088See eligibility →

Recruiting nowPhase 1

A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight

Obesity, OverweightCondition

Eloralintide, PlaceboTreatment

Singapore, United States2 locations

Eli Lilly and CompanySponsor

Updated 2026-08-20 · NCT07738614See eligibility →

Recruiting nowPhase 1, Phase 2

Safety, Tolerability and Efficacy of Semaglutide Depot in Subjects With Type-2 Diabetes Mellitus

Diabete Type 2Condition

SG Depot 2 mg, SG Depot 4 mgTreatment

Israel1 locations

Mapi Pharma Ltd.Sponsor

Updated 2026-08-20 · NCT07563699See eligibility →

Recruiting nowPhase 1, Phase 2

A First-In-Human Study of ARO-INHBE in Adults With Obesity With and Without Type 2 Diabetes Mellitus

ObesityCondition

ARO-INHBE, PlaceboTreatment

Australia, New Zealand7 locations

Arrowhead PharmaceuticalsSponsor

Updated 2026-08-18 · NCT06700538See eligibility →

Recruiting nowPhase 1

A Study to Investigate the Effect of AZD6234, AZD9550, and a Combination of AZD9550 and AZD6234 on Pharmacokinetics of Combined Oral Contraceptive Ethinyl Estradiol/Levonorgestrel in Healthy Female Participants Living With Overweight or Obesity

Healthy ParticipantsCondition

AZD6234, Ethinyl estradiol/Levonorgestrel (EE/LEVO)Treatment

United States2 locations

AstraZenecaSponsor

Updated 2026-08-18 · NCT07013643See eligibility →

Recruiting nowPhase 1

A Research Study on How UBT251 Affects Levels of Midazolam, Caffeine and Warfarin in the Blood of Participants With Excess Body Weight

Obesity, OverweightCondition

UBT251, Cocktail (Warfarin/Caffeine/Midazolam)Treatment

United States1 locations

Novo Nordisk A/SSponsor

Updated 2026-08-18 · NCT07710768See eligibility →

Recruiting nowPhase 1, Phase 2

HS235 Study in Obese Participants With Pulmonary Hypertension and Heart Failure With Preserved Ejection Fraction (HFpEF)

Pulmonary Hypertension, Heart Failure With Preserved Ejection FractionCondition

HS235, PlaceboTreatment

United States1 locations

35Pharma IncSponsor

Updated 2026-08-17 · NCT07123779See eligibility →

Recruiting nowPhase 1, Phase 2

A Study to Evaluate ALN-2232 in Participants With Obesity

ObesityCondition

ALN-2232, PlaceboTreatment

Canada1 locations

Alnylam PharmaceuticalsSponsor

Updated 2026-08-12 · NCT07463846See eligibility →

Recruiting nowPhase 1

A Trial of Oral VRB-103 Alone or in Combination With Oral Ecnoglutide (VRB-101) in Participants With Obesity or Overweight

Obesity, OverweightCondition

VRB-103, PlaceboTreatment

Australia1 locations

Verdiva Bio Dev LimitedSponsor

Updated 2026-08-11 · NCT07628127See eligibility →

Recruiting nowPhase 1

A Study to Investigate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZD1043 in Healthy Adult Participants Living With Overweight and/or Obesity.

Healthy Participants, ObesityCondition

AZD1043, PlaceboTreatment

United Kingdom, United States3 locations

AstraZenecaSponsor

Updated 2026-08-10 · NCT07511205See eligibility →

Recruiting nowPhase 1

A Study of ABBV-295 Subcutaneous Injections to Assess Adverse Events and Pharmacokinetics in Adult Participants With Obesity

ObesityCondition

ABBV-295, PlaceboTreatment

United States2 locations

AbbVieSponsor

Updated 2026-08-07 · NCT07291232See eligibility →

Recruiting nowPhase 1

A Research Study Investigating How a New Medicine NNC0113-5840 Works in People With Overweight or Obesity

Obesity, OverweightCondition

NNC0113-5840, PlaceboTreatment

United States2 locations

Novo Nordisk A/SSponsor

Updated 2026-08-04 · NCT07566390See eligibility →

Recruiting nowPhase 1

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of HRS9531 Injection in Adolescents With Obesity

Overweight and ObesityCondition

HRS9531 injection；Placebo, HRS9531 injection；PlaceboTreatment

China1 locations

Fujian Shengdi Pharmaceutical Co., Ltd.Sponsor

Updated 2026-07-31 · NCT07559136See eligibility →

Recruiting nowPhase 1

Semaglutide Delivered Epi-Intradermally by Microarray Patch (VX-201) Versus Subcutaneous Administration in Healthy Overweight and Obese Participants

Overweight and/or ObesityCondition

VX-201, semaglutide SCTreatment

United States1 locations

Terrestrial Bio, Inc.Sponsor

Updated 2026-07-31 · NCT07673900See eligibility →

Recruiting nowPhase 1

Phase Ib Study of Efsubaglutide Alfa Injection in Obese Adolescents

Adolescence ObesityCondition

Efsubaglutide Alfa 5 mg QW, Efsubaglutide Alfa 10 mg QWTreatment

China5 locations

Shanghai Yinnuo Pharmaceutical Technology Co., Ltd.Sponsor

Updated 2026-07-30 · NCT07693426See eligibility →

Recruiting nowPhase 1

A Study in People With Overweight or Obesity to Compare How 2 Different Formulations of Survodutide Are Taken up by the Body

Healthy, ObesityCondition

Formulation A, Formulation B6Treatment

United Kingdom1 locations

Boehringer IngelheimSponsor

Updated 2026-07-30 · NCT07407348See eligibility →

Recruiting nowPhase 1

A Study to See How Safe a New Medicine (NNC6989-0001) is in Healthy People Living With Overweight or Obesity

Overweight, ObesityCondition

NNC6989-0001, Placebo (NNC6989-0001)Treatment

United States1 locations

Novo Nordisk A/SSponsor

Updated 2026-07-29 · NCT07437079See eligibility →

Recruiting nowPhase 1, Phase 2

A Three-part First-in-human Trial to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GUB-UCN2 in Healthy Lean and Obese Participants and Participants With T2D

Obesity, Type 2 DiabetesCondition

GUB-UCN2, PlaceboTreatment

Germany1 locations

Gubra A/SSponsor

Updated 2026-07-29 · NCT07702890See eligibility →

Recruiting nowPhase 1

Tirzepatide s Dopaminergic Effects in Alcohol Use Disorders (AUD)

Alcohol Use Disorder (AUD)Condition

Tirzepatide, PlaceboTreatment

United States1 locations

National Institute on Alcohol Abuse and Alcoholism (NIAAA)Sponsor

Updated 2026-07-28 · NCT07559500See eligibility →

Recruiting nowPhase 1

Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ZT003 Injection Following Single and Multiple Subcutaneous Administration in Healthy Volunteers/Overweight or Obese Volunteers

HealthyCondition

ZT003 - Part1 (Single ascending dose ), ZT003 - Part 2(Multiple ascending dose )Treatment

Australia2 locations

Beijing QL Biopharmaceutical Co.,LtdSponsor

Updated 2026-07-27 · NCT07184502See eligibility →

Recruiting nowPhase 1

Pharmacogenetics of Response to GLP1R Agonists

Obesity, Diabetes Type 2Condition

Semaglutide Pen Injector [Ozempic]Treatment

United States1 locations

University of Maryland, BaltimoreSponsor

Updated 2026-07-27 · NCT05071898See eligibility →

Recruiting nowPhase 1

A Study to Test How Well Different Doses of BI 3034701 Are Tolerated by Japanese Healthy People and Japanese People With Obesity or Overweight

Healthy, ObesityCondition

BI 3034701, PlaceboTreatment

Japan3 locations

Boehringer IngelheimSponsor

Updated 2026-07-24 · NCT07693231See eligibility →

Recruiting nowPhase 1

Study of ALV-100 to Assess Safety, Tolerability, and PK/PD in Overweight/Obese Participants With or Without T2D

Overweight or Obese Adults, Overweight or Obese, Type 2 DiabetesCondition

ALV-100, PlaceboTreatment

United States2 locations

Alveus Therapeutics, Inc.Sponsor

Updated 2026-07-23 · NCT07399678See eligibility →

Recruiting nowPhase 1

Examination of How the Duration of Fasting and Temporary Stopping of GLP-1 Medications Affect the Amount of Food Left in the Stomach in People Using Liraglutide (Injected), Semaglutide (Taken by Mouth) or Semaglutide (Injected)

ObesityCondition

Liraglutide, Oral SemaglutideTreatment

United States1 locations

Novo Nordisk A/SSponsor

Updated 2026-07-21 · NCT07225816See eligibility →

Recruiting nowPhase 1

A Study of Eloralintide (LY3841136) in Participants With Overweight or Obesity

Overweight, ObesityCondition

Eloralintide, PlaceboTreatment

Germany, Sweden2 locations

Eli Lilly and CompanySponsor

Updated 2026-07-16 · NCT07665879See eligibility →

Recruiting nowPhase 1

A Phase 1 Clinical Trial to Assess the Safety of DWRX5003 and Relative Bioavailability to DWC202502 and DWC202503 in Healthy Adult Volunteers

Obesity & Overweight, Type 2 DiabetesCondition

DWRX5003, DWC202502Treatment

South Korea1 locations

Daewoong Pharmaceutical Co. LTD.Sponsor

Updated 2026-07-16 · NCT07539415See eligibility →

Recruiting nowPhase 1

Physiologic Response to Bariatric Surgery and the Impact of Adjunct Semaglutide in Adolescents

Obesity, Adolescent ObesityCondition

Injectable semaglutide or injectable tirzepatide, Standard postoperative careTreatment

United States1 locations

University of Colorado, DenverSponsor

Updated 2026-07-15 · NCT06575738See eligibility →

Recruiting nowPhase 1, Phase 2

A First-In-Human Study of ARO-ALK7 in Adults With Obesity With and Without Type 2 Diabetes Mellitus

Obesity, Diabetes Mellitus, Type 2Condition

ARO-ALK7, PlaceboTreatment

Australia, New Zealand8 locations

Arrowhead PharmaceuticalsSponsor

Updated 2026-07-08 · NCT06937203See eligibility →

Recruiting nowPhase 1

Safety and Drug Concentrations of REGN20934 in Adults With Overweight or Obesity

Overweight or ObesityCondition

REGN20934, PlaceboTreatment

United States1 locations

Regeneron PharmaceuticalsSponsor

Updated 2026-07-07 · NCT07594093See eligibility →

Recruiting nowPhase 1

Effect of Insulin Lowering on Lipogenesis

Hyperinsulinemia, Insulin ResistanceCondition

Placebo, Diazoxide Oral Suspension, 2 mg per kg per doseTreatment

United States1 locations

Columbia UniversitySponsor

Updated 2026-07-06 · NCT07403604See eligibility →

Recruiting nowPhase 1

A Study to Evaluate Safety, Tolerability and Pharmacokinetics of Orally Administered TIX100 in Healthy Subjects

Health Adult Subjects, Obesity & OverweightCondition

TIX100, PlaceboTreatment

United States1 locations

TIXiMED, Inc.Sponsor

Updated 2026-06-30 · NCT07675590See eligibility →

Recruiting nowPhase 1

A Research Study to Compare Blood Levels of Cagrilintide After Multiple Doses of Different Versions of Cagrilintide in Adults With Overweight or Obesity

Obesity, OverweightCondition

Cagrilintide D, Cagrilintide B and placebo semaglutide ITreatment

Germany1 locations

Novo Nordisk A/SSponsor

Updated 2026-06-26 · NCT07597018See eligibility →

Recruiting nowPhase 1

Evaluation of the Tolerability of Cagrilintide in Participants Not Tolerating GLP-1-RA Therapies Due to Gastrointestinal Adverse Events

Obesity, OverweightCondition

Cagrilintide, Placebo (matched to Cagrilintide)Treatment

United States11 locations

Novo Nordisk A/SSponsor

Updated 2026-06-25 · NCT07607587See eligibility →

Recruiting nowPhase 1

Single and Multiple Ascending Dose Study of AMG 513 in Participants With Obesity

Cardiometabolic DiseaseCondition

AMG 513, PlaceboTreatment

United States10 locations

AmgenSponsor

Updated 2026-06-22 · NCT06585462See eligibility →

Recruiting nowPhase 1

Study of GS-4571 in Healthy Participants, Nondiabetic Obese Participants, and Nonobese Participants With Type 2 Diabetes Mellitus (T2DM)

Weight ManagementCondition

GS-4571, PlaceboTreatment

United States3 locations

Gilead SciencesSponsor

Updated 2026-06-22 · NCT06562907See eligibility →

Recruiting nowPhase 1

Drug-drug Interaction Study of ZT002 Injection in Overweight and Obese Participants

Overweight,ObesityCondition

ZT002 injection, metformin, warfarin, ZT002 injection, rosuvastatin, digoxinTreatment

China1 locations

Beijing QL Biopharmaceutical Co.,LtdSponsor

Updated 2026-06-22 · NCT07550816See eligibility →

Recruiting nowPhase 1

A Phase 1, Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ISM8969

Healthy Subjects (HS), Obese Adult Participants at Risk of Cardiovascular DiseaseCondition

ISM8969 tablets or placebo, ISM8969 tablets or placeboTreatment

Australia1 locations

InSilico Medicine Hong Kong LimitedSponsor

Updated 2026-06-22 · NCT07581431See eligibility →

Recruiting nowPhase 1

A Study to Evaluate the Safety and Tolerability of Different Doses of CX11 Tablets

Obesity & OverweightCondition

CX11, PlaceboTreatment

United States2 locations

Corxel PharmaceuticalsSponsor

Updated 2026-06-17 · NCT07652047See eligibility →

Recruiting nowPhase 1, Phase 2

Interleukine-2 (IL-2) Plus Semaglutide in Alzheimer's Disease

Alzheimer Dementia (AD)Condition

IL-2 (Aldesleukin), Semaglutide Plus IL-2Treatment

United States1 locations

The Methodist Hospital Research InstituteSponsor

Updated 2026-06-16 · NCT07651319See eligibility →

Recruiting nowPhase 1

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MBX 4291 in Adult Participants With Obesity

ObesityCondition

MBX 4291, PlaceboTreatment

United States4 locations

MBX BiosciencesSponsor

Updated 2026-06-09 · NCT07142707See eligibility →

Recruiting nowPhase 1

A Research Study Investigating the Effect of NNC0497-0040 in Healthy Participants, Participants With Overweight or Obesity, and Participants With Type 1 Diabetes With Overweight or Obesity

Type 1 Diabetes (T1D), OverweightCondition

NNC0497-0040, PlaceboTreatment

Germany1 locations

Novo Nordisk A/SSponsor

Updated 2026-06-04 · NCT07578584See eligibility →

Recruiting nowPhase 1, Phase 2

A Phase 1/2a Study of WVE-007 in Adults Living With Overweight or Obesity

Overweight and ObesityCondition

WVE-007Treatment

Moldova, Romania6 locations

Wave Life Sciences USA, Inc.Sponsor

Updated 2026-06-02 · NCT06842186See eligibility →

Recruiting nowPhase 1, Phase 2

A Study of MET233 in Combination With MET097 in Individuals With Obesity or Overweight With or Without Diabetes

Obesity and Obesity-related Medical ConditionsCondition

MET233 and MET097, PlaceboTreatment

United States1 locations

PfizerSponsor

Updated 2026-06-01 · NCT06924320See eligibility →

Recruiting nowPhase 1

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of a Single Dose of IBIO-600 in Overweight or Obese Adults

Overweight , ObesityCondition

IBIO-600, PlaceboTreatment

Australia1 locations

iBio, Inc.Sponsor

Updated 2026-05-29 · NCT07487376See eligibility →

Recruiting nowPhase 1

Metabolic Effects of Angiotensin-(1-7)

Obesity, Insulin ResistanceCondition

Angiotensin-(1-7), SalineTreatment

United States1 locations

Vanderbilt UniversitySponsor

Updated 2026-05-22 · NCT02646475See eligibility →

This page shows the first 60 studies. Use the full search to filter all matches.

How current is this page?

The page is rebuilt from the public registry feed. Each trial card shows the registry update date. Recruitment can still change between builds.

Does appearing here mean I qualify?

No. These pages are discovery indexes. Only a study team can confirm eligibility after reviewing the complete protocol criteria.

PHASE1 clinical trials

Current studies

Related phases